Hospira Goes Negative
Hospira (NYS: HSP) reported earnings on May 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Hospira met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded slightly. Non-GAAP earnings per share grew. GAAP earnings per share dropped to a loss.
Margins contracted across the board.
Hospira booked revenue of $988.3 million. The nine analysts polled by S&P Capital IQ expected revenue of $982.9 million on the same basis. GAAP reported sales were 8.5% lower than the prior-year quarter's $965.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.52. The 13 earnings estimates compiled by S&P Capital IQ predicted $0.44 per share. Non-GAAP EPS of $0.52 for Q1 were 11% higher than the prior-year quarter's $0.47 per share. GAAP EPS were -$0.46 for Q1 compared to $0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 17.0%, much worse than the prior-year quarter. Operating margin was -12.4%, much worse than the prior-year quarter. Net margin was -8.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $1.03 billion. On the bottom line, the average EPS estimate is $0.51.
Next year's average estimate for revenue is $4.11 billion. The average EPS estimate is $2.03.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 132 members out of 160 rating the stock outperform, and 28 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Hospira a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $30.54.
- Add Hospira to My Watchlist.
The article Hospira Goes Negative originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.